A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer - Concepedia

Concepedia

Publication | Open Access

A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

DOI Full Paper Access

130

Citations

13

References

2011

Year

David S. Hong, Razelle Kurzrock, Yun Oh, Jennifer J. Wheler, Aung Naing, Les Brail, Sophie Callies, Valérie André, Sunil Kadam, Aejaz Nasir,

Clinical Cancer Research

Abstract

LY2275796 was well tolerated up to 1,000 mg. Because tumor eIF-4E expression was decreased, but no tumor response observed, LY2275796 should be studied combined with other treatment modalities.

References

	Year	Citations

Page 1